Clinical Trial Update: Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for enfortumab vedotin in patients with metastatic or unresectable penile squamous cell carcinoma, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Penile Squamous Cell Carcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8 | Phase 2 | Status: RECRUITING